#phase 3

2 stories

Clinical Trials April 7, 2026 · View digest

Eli Lilly's Retatrutide Hits All Endpoints in Phase 3 Type 2 Diabetes Trial

Retatrutide met its primary endpoint of superior A1C reduction and all key secondary endpoints at 40 weeks compared with placebo in type 2 diabetes patients, also demonstrating significant weight loss.

Clinical Trials April 3, 2026 · View digest

Retatrutide Achieves 28.7% Weight Loss and Knee Pain Reduction in TRIUMPH-4 Phase 3 Trial

Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.